Standard BioTools Inc. (NASDAQ:LAB) Director Casdin Partners Master Fund, L Acquires 500,000 Shares

Standard BioTools Inc. (NASDAQ:LABGet Free Report) Director Casdin Partners Master Fund, L bought 500,000 shares of the stock in a transaction that occurred on Wednesday, August 21st. The stock was acquired at an average price of $1.90 per share, for a total transaction of $950,000.00. Following the completion of the transaction, the director now owns 53,025,821 shares in the company, valued at $100,749,059.90. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Casdin Partners Master Fund, L also recently made the following trade(s):

  • On Monday, August 19th, Casdin Partners Master Fund, L purchased 250,000 shares of Standard BioTools stock. The shares were purchased at an average price of $1.85 per share, for a total transaction of $462,500.00.
  • On Wednesday, August 14th, Casdin Partners Master Fund, L purchased 1,200,000 shares of Standard BioTools stock. The shares were purchased at an average price of $1.59 per share, for a total transaction of $1,908,000.00.
  • On Monday, August 12th, Casdin Partners Master Fund, L purchased 500,000 shares of Standard BioTools stock. The shares were purchased at an average price of $1.64 per share, for a total transaction of $820,000.00.
  • On Friday, August 9th, Casdin Partners Master Fund, L purchased 525,408 shares of Standard BioTools stock. The shares were purchased at an average price of $1.61 per share, for a total transaction of $845,906.88.
  • On Wednesday, August 7th, Casdin Partners Master Fund, L purchased 500,000 shares of Standard BioTools stock. The shares were purchased at an average price of $1.57 per share, for a total transaction of $785,000.00.
  • On Friday, August 2nd, Casdin Partners Master Fund, L purchased 1,000,000 shares of Standard BioTools stock. The shares were purchased at an average price of $1.63 per share, for a total transaction of $1,630,000.00.
  • On Monday, August 5th, Casdin Partners Master Fund, L purchased 200,000 shares of Standard BioTools stock. The shares were purchased at an average price of $1.58 per share, for a total transaction of $316,000.00.

Standard BioTools Price Performance

Shares of LAB traded up $0.08 during trading hours on Wednesday, hitting $1.94. 3,157,292 shares of the company were exchanged, compared to its average volume of 2,708,076. The company has a market capitalization of $718.62 million, a PE ratio of -1.80 and a beta of 1.67. The firm has a fifty day simple moving average of $1.93 and a 200-day simple moving average of $2.33. Standard BioTools Inc. has a one year low of $1.21 and a one year high of $3.16.

Analyst Upgrades and Downgrades

Separately, TD Cowen reduced their price objective on Standard BioTools from $3.50 to $2.75 and set a “buy” rating for the company in a research note on Thursday, August 1st.

View Our Latest Analysis on LAB

Institutional Investors Weigh In On Standard BioTools

Several large investors have recently modified their holdings of LAB. Vanguard Group Inc. boosted its position in shares of Standard BioTools by 215.3% in the first quarter. Vanguard Group Inc. now owns 13,034,043 shares of the company’s stock worth $35,322,000 after buying an additional 8,900,104 shares during the period. Sumitomo Mitsui Trust Holdings Inc. boosted its position in shares of Standard BioTools by 20.2% in the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 10,642,271 shares of the company’s stock worth $18,837,000 after buying an additional 1,788,780 shares during the period. Nikko Asset Management Americas Inc. acquired a new stake in shares of Standard BioTools in the first quarter worth $23,993,000. Nan Fung Group Holdings Ltd acquired a new stake in shares of Standard BioTools in the first quarter worth $5,103,000. Finally, Hollow Brook Wealth Management LLC boosted its position in shares of Standard BioTools by 5.0% in the fourth quarter. Hollow Brook Wealth Management LLC now owns 1,874,405 shares of the company’s stock worth $4,142,000 after buying an additional 88,648 shares during the period. 53.74% of the stock is owned by institutional investors.

About Standard BioTools

(Get Free Report)

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.

See Also

Insider Buying and Selling by Quarter for Standard BioTools (NASDAQ:LAB)

Receive News & Ratings for Standard BioTools Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Standard BioTools and related companies with MarketBeat.com's FREE daily email newsletter.